{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T11:28:37Z","timestamp":1787138917493,"version":"build-2736575974"},"reference-count":42,"publisher":"MDPI AG","issue":"16","license":[{"start":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T00:00:00Z","timestamp":1787097600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background: Chordoma is a rare malignant bone tumor thought to arise from remnants of the embryonic notochord. Its management remains challenging because of its proximity to critical neurovascular structures and its high propensity for local recurrence. Current standard treatment consists of maximal safe resection followed by radiotherapy, yet durable disease control remains difficult to achieve in many patients. Emerging evidence suggests that cyclin-dependent kinase inhibitor 2A (CDKN2A) loss is a recurrent molecular event in chordoma and may serve as both a prognostic biomarker and a therapeutic target. Methods: A literature search was performed by acquiring articles containing \u201c(CDKN2A or p16) AND (chordoma or notochordal tumor)\u201d, and \u201cchordoma 9p21\u201d. Of the 41 articles retrieved, 17 met the inclusion criteria. Results: Homozygous and heterozygous CDKN2A deletions were frequently identified in chordoma using fluorescence in situ hybridization and genomic sequencing approaches. These alterations were commonly associated with loss of p16^INK4A expression, the protein product of CDKN2A, supporting a role in tumorigenesis and disease progression. Epigenetic mechanisms may also contribute to reduced p16^INK4A expression in a subset of tumors. Preclinical studies in CDKN2A-deficient chordoma cell lines and patient-derived xenografts demonstrated sensitivity to cyclin-dependent kinase 4 and 6 (CDK4\/6) inhibitors, including palbociclib, flavopiridol, and abemaciclib. Combination strategies pairing palbociclib with buparlisib or rapamycin produced greater antitumor effects, particularly in p16^INK4A- and PTEN-deficient models. In addition, CDKN2A loss has been associated with adverse clinical features in selected cohorts, although its independent prognostic significance remains unclear. Available preclinical evidence further suggests that chordomas lacking p16^INK4A expression and retaining retinoblastoma pathway dependence may be particularly susceptible to CDK4\/6 inhibition. Conclusions: CDKN2A loss is a recurrent molecular alteration in chordoma that is associated with reduced p16^INK4A expression, adverse clinicopathologic features, and less favorable outcomes in selected cohorts, although its independent prognostic significance remains inconsistent. Preclinical data support CDK4\/6 inhibition, particularly in biomarker-selected CDKN2A-deficient tumors, and suggest that combination approaches targeting complementary pathways such as PI3K\/mTOR may further enhance therapeutic efficacy. Together, these findings support the clinical relevance of CDKN2A as both a prognostic biomarker and a promising therapeutic target in chordoma.<\/jats:p>","DOI":"10.3390\/cancers18162688","type":"journal-article","created":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T11:04:12Z","timestamp":1787137452000},"page":"2688","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A Pathway to Chordoma Treatment: A Review on CDKN2A and Therapeutic Targeting"],"prefix":"10.3390","volume":"18","author":[{"given":"Muneeb","family":"Mohiuddin","sequence":"first","affiliation":[{"name":"Department of Neurosurgery, University of Miami, Miami, FL 33136, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Vaca","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, University of Miami, Miami, FL 33136, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-5999-2329","authenticated-orcid":false,"given":"Elijah","family":"Haynal","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Loma Linda University, Loma Linda, CA 92354, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Othman","family":"Bin-Alamer","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, University of Utah, Salt Lake City, UT 84132, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Zaki","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Loma Linda University, Loma Linda, CA 92354, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hussam","family":"Abou-Al-Shaar","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, McGovern Medical School, Houston, TX 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgios A.","family":"Zenonos","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, University of Pittsburgh Medical Center, Pittsburgh, PA 15213, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hector A.","family":"Perez","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology-Head and Neck Surgery, Loma Linda University, Loma Linda, CA 92350, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7172-6963","authenticated-orcid":false,"given":"Miguel","family":"Lopez-Gonzalez","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Loma Linda University, Loma Linda, CA 92354, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zachary C.","family":"Gersey","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Loma Linda University, Loma Linda, CA 92354, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,8,19]]},"reference":[{"key":"ref_1","unstructured":"Tenny, S., and Varacallo, M.A. (2026). Chordoma, StatPearls."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s11060-020-03511-x","article-title":"Descriptive epidemiology of chordomas in the United States","volume":"148","author":"Das","year":"2020","journal-title":"J. Neuro-Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"e69","DOI":"10.1016\/S1470-2045(11)70337-0","article-title":"Chordoma: Current concepts, management, and future directions","volume":"13","author":"Walcott","year":"2012","journal-title":"Lancet Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1016\/0092-8674(95)90214-7","article-title":"Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest","volume":"83","author":"Quelle","year":"1995","journal-title":"Cell"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1080\/15384101.2015.1014149","article-title":"Cyclin-dependent kinase pathway aberrations in diverse malignancies: Clinical and molecular characteristics","volume":"14","author":"Kato","year":"2015","journal-title":"Cell Cycle"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"5001","DOI":"10.1093\/emboj\/17.17.5001","article-title":"The alternative product from the human CDKN2A locus, p14(ARF), participates in a regulatory feedback loop with p53 and MDM2","volume":"17","author":"Stott","year":"1998","journal-title":"EMBO J."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Choy, E., MacConaill, L.E., Cote, G.M., Le, L., Shen, J., Nielsen, P., Iafrate, A., Garraway, L., Hornicek, F., and Duan, Z. (2014). Genotyping cancer-associated genes in chordoma identifies mutations in oncogenes and areas of chromosomal loss involving CDKN2A, PTEN, and SMARCB1. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0101283"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1016\/j.jaad.2014.06.036","article-title":"Increased prevalence of lung, breast, and pancreatic cancers in addition to melanoma risk in families bearing the cyclin-dependent kinase inhibitor 2A mutation: Implications for genetic counseling","volume":"71","author":"Potrony","year":"2014","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Stenman, A., Yang, M., Paulsson, J.O., Zedenius, J., Paulsson, K., and Juhlin, C.C. (2021). Pan-Genomic Sequencing Reveals Actionable CDKN2A\/2B Deletions and Kataegis in Anaplastic Thyroid Carcinoma. Cancers, 13.","DOI":"10.3390\/cancers13246340"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"(2016). The Cancer Genome Atlas Research Network. Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma. N. Engl. J. Med., 374, 135\u2013145.","DOI":"10.1056\/NEJMoa1505917"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Le, L.P., Nielsen, G.P., Rosenberg, A.E., Thomas, D., Batten, J., Deshpande, V., Schwab, J., Duan, Z., Xavier, R., and Hornicek, F. (2011). Recurrent chromosomal copy number alterations in sporadic chordomas. PLoS ONE, 6.","DOI":"10.1371\/journal.pone.0018846"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1002\/cjp2.156","article-title":"Frequent alterations in p16\/CDKN2A identified by immunohistochemistry and FISH in chordoma","volume":"6","author":"Cottone","year":"2020","journal-title":"J. Pathol. Clin. Res."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.3171\/2023.1.JNS222180","article-title":"The mutational landscape of skull base and spinal chordomas and the identification of potential prognostic and theranostic biomarkers","volume":"139","author":"Passeri","year":"2023","journal-title":"J. Neurosurg."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1593\/neo.12526","article-title":"High-resolution whole-genome analysis of skull base chordomas implicates FHIT loss in chordoma pathogenesis","volume":"14","author":"Diaz","year":"2012","journal-title":"Neoplasia"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Huo, X., Guo, T., Wang, K., Yao, B., Li, D., Li, H., Chen, W., Wang, L., and Wu, Z. (2022). Methylation-based reclassification and risk stratification of skull-base chordomas. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.960005"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1038\/s41467-021-21026-5","article-title":"Whole genome sequencing of skull-base chordoma reveals genomic alterations associated with recurrence and chordoma-specific survival","volume":"12","author":"Bai","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1186\/s40478-023-01610-0","article-title":"DNA methylation, combined with RNA sequencing, provide novel insight into molecular classification of chordomas and their microenvironment","volume":"11","author":"Baluszek","year":"2023","journal-title":"Acta Neuropathol. Commun."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Hsia, B., Bitar, G., Alshaka, S.A., Kim, J., Valenia-Sanchez, B., Faraji, F., Brandel, M., Sato, M., Crawford, J., and Levy, M. (2025). Genomic Characterization of Chordoma: Insights from the AACR Project GENIE Database. Cancers, 17.","DOI":"10.3390\/cancers17030536"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"e70033","DOI":"10.1002\/cncr.70033","article-title":"Mutational analysis of primary and advanced chordoma tissue using next-generation sequencing","volume":"131","author":"Chan","year":"2025","journal-title":"Cancer"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1002\/path.2679","article-title":"Methylthioadenosine phosphorylase and activated insulin-like growth factor-1 receptor\/insulin receptor: Potential therapeutic targets in chordoma","volume":"220","author":"Sommer","year":"2010","journal-title":"J. Pathol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.3171\/2018.3.JNS172321","article-title":"Prospective validation of a molecular prognostication panel for clival chordoma","volume":"130","author":"Zenonos","year":"2019","journal-title":"J. Neurosurg."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1055\/s-0041-1730958","article-title":"An Integrated Management Paradigm for Skull Base Chordoma Based on Clinical and Molecular Characteristics","volume":"82","author":"Abdallah","year":"2021","journal-title":"J. Neurol. Surg. B Skull Base"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Seeling, C., Mosca, E., Mantel, E., Moller, P., Barth, T.F.E., and Mellert, K. (2023). Prognostic Relevance and In Vitro Targeting of Concomitant PTEN and p16 Deficiency in Chordomas. Cancers, 15.","DOI":"10.3390\/cancers15071977"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"3823","DOI":"10.1158\/0008-5472.CAN-14-3270","article-title":"Preclinical Characterization of Novel Chordoma Cell Systems and Their Targeting by Pharmocological Inhibitors of the CDK4\/6 Cell-Cycle Pathway","volume":"75","author":"Goerttler","year":"2015","journal-title":"Cancer Res."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Passeri, T., Dahmani, A., Masliah-Planchon, J., El Botty, R., Courtois, L., Vacher, S., Marangoni, E., Nemati, F., Roman-Roman, S., and Adle-Biassette, H. (2022). In vivo efficacy assessment of the CDK4\/6 inhibitor palbociclib and the PLK1 inhibitor volasertib in human chordoma xenografts. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.960720"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s11060-020-03418-7","article-title":"Rationale for the advancement of PI3K pathway inhibitors for personalized chordoma therapy","volume":"147","author":"Michmerhuizen","year":"2020","journal-title":"J. Neuro-Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"4649","DOI":"10.2147\/OTT.S252990","article-title":"Deficiency of PTEN and CDKN2A Tumor-Suppressor Genes in Conventional and Chondroid Chordomas: Molecular Characteristics and Clinical Relevance","volume":"13","author":"Yang","year":"2020","journal-title":"OncoTargets Ther."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1038\/s41467-017-01026-0","article-title":"The driver landscape of sporadic chordoma","volume":"8","author":"Tarpey","year":"2017","journal-title":"Nat. Commun."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1038\/sj.bjc.6605019","article-title":"Potential therapeutic targets for chordoma: PI3K\/AKT\/TSC1\/TSC2\/mTOR pathway","volume":"100","author":"Presneau","year":"2009","journal-title":"Br. J. Cancer"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1158\/2159-8290.CD-19-1390","article-title":"The genomic landscape of intrinsic and acquired resistance to cyclin-dependent kinase 4\/6 inhibitors in patients with hormone receptor-positive metastatic breast cancer","volume":"10","author":"Wander","year":"2020","journal-title":"Cancer Discov."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1158\/0008-5472.CAN-15-0728","article-title":"Early adaptation and acquired resistance to CDK4\/6 inhibition in estrogen receptor-positive breast cancer","volume":"76","author":"Palafox","year":"2016","journal-title":"Cancer Res."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1002\/path.5739","article-title":"AZD8055 enhances in vivo efficacy of afatinib in chordomas","volume":"255","author":"Zhao","year":"2021","journal-title":"J. Pathol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"4540","DOI":"10.1158\/0008-5472.CAN-20-1387","article-title":"Inhibition of histone H3K27 demethylases inactivates brachyury (TBXT) and promotes chordoma cell death","volume":"80","author":"Cottone","year":"2020","journal-title":"Cancer Res."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1200\/JCO.2011.35.3656","article-title":"Phase II study of imatinib in advanced chordoma","volume":"30","author":"Stacchiotti","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"7120","DOI":"10.1038\/s41467-026-69708-2","article-title":"Tazemetostat, an EZH2 inhibitor, in solid tumors harboring SWI\/SNF alterations: A phase II basket study","volume":"17","author":"Gounder","year":"2026","journal-title":"Nat. Commun."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1200\/JCO-25-02719","article-title":"Efficacy and safety of camrelizumab plus apatinib in patients with refractory chordoma: A phase II clinical trial","volume":"44","author":"Yang","year":"2026","journal-title":"J. Clin. Oncol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"105498","DOI":"10.1016\/j.esmoop.2025.105498","article-title":"CDK4\/6 inhibition in advanced chordoma: Final results of the NCT PMO-1601 trial","volume":"10","author":"Teleanu","year":"2025","journal-title":"ESMO Open"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"v538","DOI":"10.1093\/annonc\/mdx387.051","article-title":"CDK4\/6 Inhibition in Locally Advanced\/Metastatic Chordoma (NCT-PMO-1601)","volume":"28","author":"Barth","year":"2017","journal-title":"Ann. Oncol."},{"key":"ref_39","unstructured":"(2026, August 17). Abemaciclib for Bone and Soft Tissue Sarcoma with Cyclin-Dependent Kinase (CDK) Pathway Alteration. ClinicalTrials.gov. Identifier: NCT04040205, Available online: https:\/\/clinicaltrials.gov\/study\/NCT04040205."},{"key":"ref_40","unstructured":"(2026, August 17). Trial of Palbociclib in Second Line of Advanced Sarcomas with CDK4 Overexpression (PalboSarc). ClinicalTrials.gov. Identifier: NCT03242382, Available online: https:\/\/clinicaltrials.gov\/study\/NCT03242382."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.ajpath.2022.12.012","article-title":"SMARCB1 Loss in Poorly Differentiated Chordomas Drives Tumor Progression","volume":"193","author":"Walhart","year":"2023","journal-title":"Am. J. Pathol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/s00432-023-05560-x","article-title":"A retrospective study on the mechanism underlying quick transfer from response to resistance in a repeated recurrent chordoma patient with molecular alterations treated with palbociclib","volume":"150","author":"Zhong","year":"2024","journal-title":"J. Cancer Res. Clin. Oncol."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/16\/2688\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T11:12:35Z","timestamp":1787137955000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/16\/2688"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,19]]},"references-count":42,"journal-issue":{"issue":"16","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["cancers18162688"],"URL":"https:\/\/doi.org\/10.3390\/cancers18162688","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,19]]}}}